Tomer was awarded a Fulbright Postdoctoral Fellowship to pursue his research project titled “Tri & Bi Metallic Anticancer Prodrugs that Combine Chemotherapy and Immunotherapy”. He received his B.Sc. in Pharmacy and M.Sc. in Medicinal Chemistry from The Hebrew University of Jerusalem under the IDR excellence program[ES1]  and is the recipient of several awards including Clore Foundation Scholarship for outstanding PhD student, Aharon and Ephraim Katzir Grant from the Israel Academy of Sciences and Humanities and the Kaye Innovation Award.

Tomer’s PhD research, under the supervision of Professor Dan Gibson, focused on bio-inorganic chemistry aiming to develop novel oral platinum-based metal complexes for cancer treatment with improved anticancer efficacy and minimal side effects.

In his postdoctoral studies, he aims to further develop the field of metals in medicine by combining several metal complexes to a single prodrug that have the ability of shrinking primary tumors as well as induction of the adaptive immune system that can drastically suppress metastatic neoplasm to allow the long-sought goal of creating a cancer vaccine. Tomer’s recent publications include:

• Oral Anticancer Heterobimetallic PtIV-AuI Complexes Show High In Vivo Activity and Low Toxicity. Angewandte Chemie-International Edition (2023)

• Are Pt(IV) prodrugs that release Combretastatin A4 true multi-action prodrugs? Journal of Medicinal Chemistry (2021)

• Expanding the Arsenal of Pt-IV Anticancer Agents: Multi-action Pt-IV Anticancer Agents with Bioactive Ligands Possessing a Hydroxy Functional Group. Angewandte Chemie-International Edition (2019)